MA39710A - Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin - Google Patents

Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin

Info

Publication number
MA39710A
MA39710A MA039710A MA39710A MA39710A MA 39710 A MA39710 A MA 39710A MA 039710 A MA039710 A MA 039710A MA 39710 A MA39710 A MA 39710A MA 39710 A MA39710 A MA 39710A
Authority
MA
Morocco
Prior art keywords
treatment
inflammatory bowel
bowel disease
topical composition
probiotic
Prior art date
Application number
MA039710A
Other languages
English (en)
Inventor
Andrea Biffi
Original Assignee
Sofar Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sofar Spa filed Critical Sofar Spa
Publication of MA39710A publication Critical patent/MA39710A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition topique contenant un probiotique et de l'acide hyaluronique ou un sel pharmaceutiquement acceptable de celui-ci, pour une utilisation dans le traitement et/ou la prévention d'une maladie inflammatoire de l'intestin.
MA039710A 2014-04-23 2015-04-21 Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin MA39710A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI20140751 2014-04-23

Publications (1)

Publication Number Publication Date
MA39710A true MA39710A (fr) 2015-10-29

Family

ID=50981755

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039710A MA39710A (fr) 2014-04-23 2015-04-21 Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin

Country Status (6)

Country Link
US (2) US11464814B2 (fr)
EP (1) EP3134072A1 (fr)
JP (1) JP2017513906A (fr)
CA (1) CA2944118C (fr)
MA (1) MA39710A (fr)
WO (1) WO2015162570A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
MA39710A (fr) * 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
MA45327A (fr) 2016-05-13 2019-03-20 Sofar Spa Utilisation de probiotiques pour améliorer l'absorption des protéines
MA45288A (fr) 2016-06-08 2019-04-17 Sofar Spa Nouvelle utilisation médicale de probiotiques
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
IT201600131819A1 (it) * 2016-12-28 2018-06-28 Metis Healthcare S R L Preparazione per spray orale
IT201700101704A1 (it) * 2017-09-12 2019-03-12 Sofar Spa Nuovo uso per trattamento delle infezioni da clostridium difficile
CA3084735A1 (fr) * 2017-12-06 2019-06-13 Lac2biome S.r.l. Composition a base de probiotiques et ses utilisations
CN111973636A (zh) * 2019-05-21 2020-11-24 王飞 一种肛肠凝胶及其制备方法
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
US20230149481A1 (en) * 2020-03-31 2023-05-18 Servatus Ltd Combination therapy for inflammatory bowel disease

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0517363A (ja) * 1991-07-11 1993-01-26 Yakult Honsha Co Ltd 抗炎症剤及びそれを含有する化粧料
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
CN1066926C (zh) 1996-04-08 2001-06-13 钟春燕 将椰子水发酵制作的食用纤维及其生产方法
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
CZ9900769A3 (cs) 1999-03-04 2000-10-11 Petr Ing. Drsc. Hušek Použití špičky s filtrem k vytvoření sloupce sorbentu s definovaným objemem v prostoru pod filtrem
US20020090416A1 (en) 1999-03-09 2002-07-11 Philip Connolly Method of enhancing absorption and utilization of protein
IT1307850B1 (it) 1999-03-15 2001-11-19 Italmed Di Galli Giovanna E Pa Composizione farmaceutica a base di fermenti lattici e carboidratinon assorbibili contenente un sale di calcio ed un sale di alluminio
EP1145643A1 (fr) 2000-04-10 2001-10-17 Phillip Connolly Concentré de lactoprotéines amelioré
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
RU2182008C1 (ru) 2000-10-20 2002-05-10 Самойленко Игорь Иннокентьевич Вводимая перорально, ректально или интравагинально композиция, содержащая живые бактерии
US20030092163A1 (en) 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
FI20020078A (fi) 2002-01-15 2003-07-16 Danisco Immuunijärjestelmän stimulointi polydextroosilla
US6881419B2 (en) 2002-04-09 2005-04-19 William E. Lovett Vitamin formulation for enhancing bone strength
AU2002309180A1 (en) * 2002-04-24 2003-11-10 Medicarb Ab Composition and kit for the treatment of inflammatory bowel diseases
DE60330781D1 (de) 2002-08-06 2010-02-11 Danisco Anwendung von lactobacillus zur herstellung von exopolysacchariden in nahrungsmittel und pharmazeutische zusammensetzungen
AU2002951270A0 (en) 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
WO2005001109A2 (fr) 2003-05-06 2005-01-06 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Procedes et compositions permettant de detecter des microbes dans des echantillons fecaux
US20100112088A1 (en) 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress
EP1730302A2 (fr) 2004-02-27 2006-12-13 Stichting Laboratorium voor Infectieziekten Methode de detection de microorganismes dans des echantillons fecaux
WO2005091933A2 (fr) * 2004-03-04 2005-10-06 E-L Management Corporation Methode de traitement de la peau au moyen d'extrait de lactobacillus
EP2280085A3 (fr) 2004-11-01 2011-02-23 George Mason University Compositions et méthodes pour le diagnostic de troubles du colon
CN101175416A (zh) 2005-04-06 2008-05-07 诺瓦提斯公司 从营养方面改善葡萄糖控制和胰岛素作用的方法和组合物
FI20051319L (fi) 2005-12-22 2007-06-23 Cyflo Oy Menetelmä eläimen ja/tai ihmisen ravitsemuksen ja hyvinvoinnin ja eläinten tuottavuuden seuraamiseksi ja kehittämiseksi
CN1840206A (zh) 2006-01-19 2006-10-04 上海交通大学 人源菌群仔猪模型的构建及仔猪肠道中菌群分子检测方法
ES2426038T3 (es) 2006-02-21 2013-10-18 National University Corporation University Of Toyama Procedimiento rápido para identificar el microorganismo causante de una enfermedad infecciosa
EP1992645A4 (fr) * 2006-02-24 2011-03-09 Q P Corp Nouvel acide hyaluronique a faible poids moleculaire et/ou sel de celui-ci, et preparation cosmetique, composition pharmaceutique et composition alimentaire chacune utilisant ledit acide
WO2007140621A1 (fr) 2006-06-09 2007-12-13 Nutravital Inc. Compositions probiotiques et leurs utilisations
US20080069861A1 (en) 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
US20080081035A1 (en) 2006-10-03 2008-04-03 National Enzyme Company Therapeutic protease compositions
CA2673120C (fr) 2006-12-18 2012-08-07 Advanced Bionutrition Corporation Produit alimentaire sec contenant un probiotique vivant
EP1972208A1 (fr) 2007-03-16 2008-09-24 Kirin Holdings Kabushiki Kaisha Composition pour améliorer la flore microbienne intestinale
KR20090109131A (ko) 2007-03-27 2009-10-19 더 프록터 앤드 갬블 캄파니 생균제를 투여하기 위한 방법 및 키트
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
RU2469558C2 (ru) 2007-07-06 2012-12-20 Н.В. Нютрисиа Применение пробиотиков и волокон при диарее
US8193155B2 (en) * 2009-02-09 2012-06-05 Elc Management, Llc Method and compositions for treating skin
US20090098088A1 (en) 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
CN101240315A (zh) 2008-02-21 2008-08-13 上海交通大学 检测药物防癌效果的非损伤性分子方法
WO2009134948A1 (fr) 2008-05-01 2009-11-05 The Procter & Gamble Company Procédés et kits destinés au traitement de troubles inflammatoires de l’intestin
WO2010008272A1 (fr) 2008-07-15 2010-01-21 N.V. Nutricia Traitement de troubles du transit intestinal
JP2010161944A (ja) 2009-01-13 2010-07-29 Syngen Biotech Co Ltd 新型カゼイ菌の亜種（ｓｇ９６）及びこれを含有する菌抑制組成物及びその用途
EP2403510B1 (fr) 2009-03-05 2020-02-26 Probiotical S.p.A. Souches bactériennes ayant une grande activité anti-inflammatoire
WO2010103132A1 (fr) 2009-03-10 2010-09-16 Hero España, S.A. Isolement, identification et caractérisation de souches ayant une activité probiotique à partir de fèces de nourrissons alimentés exclusivement avec du lait maternel
EP2480255B1 (fr) 2009-09-23 2017-11-22 Thomas Julius Borody Thérapie pour infections entériques chroniques
CN104206946A (zh) 2009-11-12 2014-12-17 雀巢产品技术援助有限公司 用于促进肠微生物群平衡和健康的营养组合物
JP5932662B2 (ja) 2009-12-22 2016-06-08 プロビ アクティエボラーグ 穀物ベースフラクション及びプロバイオティックを含む非発酵組成物、並びにそれらの使用
US8575130B2 (en) * 2010-01-04 2013-11-05 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
ITUD20100112A1 (it) * 2010-06-09 2011-12-10 Farma Derma S R L Preparazione per uso vaginale e rettale e relativo procedimento di produzione
WO2012135499A1 (fr) 2011-03-31 2012-10-04 Ganeden Biotech, Inc. Compositions nutritionnelles probiotiques pour l'activité sportive
WO2012154738A1 (fr) 2011-05-09 2012-11-15 The Cleveland Clinic Foundation Composition et procédé pour améliorer la santé intestinale
GB201219873D0 (en) 2012-11-05 2012-12-19 Multigerm Uk Entpr Ltd Diverticulitis treatment
CN102919922A (zh) 2012-11-08 2013-02-13 黑龙江省轻工科学研究院 一种复合益生菌发酵蓝莓果汁粉的制备方法
JP2016511272A (ja) 2013-03-05 2016-04-14 レイクスユニフェルシテイト フローニンゲン 炎症を抑制するためのフィーカリバクテリウム・パラウスニッチィーｈｔｆ−ｆ（ｄｓｍ２６９４３）の使用
BR112015032918B1 (pt) 2013-07-02 2021-09-28 Austrianova Singapore Pte Ltd Métodos para preparação de células encapsuladas para liofilização, composição e seus usos
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
ITMI20131473A1 (it) 2013-09-06 2015-03-07 Sofar Spa Metodo per valutare gli effetti di una composizione comprendente microrganismi sul microbiota intestinale
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
AU2015258769A1 (en) 2014-05-12 2016-12-01 Medlab Ip Pty Ltd Probiotic compositions and uses thereof for treatment of obesity-related disorders
EP2990045B1 (fr) 2014-08-26 2016-11-16 Chr. Hansen A/S Bifidobacterium animalis subsp. lactis destiné à être utilisé pour réduire la douleur abdominale chez une femme ménopausée
MA45327A (fr) 2016-05-13 2019-03-20 Sofar Spa Utilisation de probiotiques pour améliorer l'absorption des protéines
WO2017195182A1 (fr) 2016-05-13 2017-11-16 Sofar S.P.A. Utilisation de probiotiques pour améliorer l'absorption des protéines
MA45288A (fr) 2016-06-08 2019-04-17 Sofar Spa Nouvelle utilisation médicale de probiotiques
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
ES2965306T3 (es) 2016-12-16 2024-04-12 Gervais Danone Sa Composición probiótica que comprende cepas de Lactobacillus rhamnosus y Lactobacillus paracasei
WO2019019961A1 (fr) 2017-07-26 2019-01-31 海思科医药集团股份有限公司 Microflore destinée à la prévention et au traitement d'une réaction du tube digestif et/ou de la peau et son utilisation
IT201700101704A1 (it) 2017-09-12 2019-03-12 Sofar Spa Nuovo uso per trattamento delle infezioni da clostridium difficile
CA3084735A1 (fr) 2017-12-06 2019-06-13 Lac2biome S.r.l. Composition a base de probiotiques et ses utilisations
CN108743851A (zh) 2018-08-09 2018-11-06 深圳市博奥生物科技有限公司 一种复合益生菌粉的制备方法及复合益生菌粉
IT201900016811A1 (it) 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
IT201900016865A1 (it) 2019-09-20 2021-03-20 Sofar Spa Composizioni a base di ceppi batterici e loro uso come antinfiammatori
IT201900016805A1 (it) 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
IT201900016850A1 (it) 2019-09-20 2021-03-20 Sofar Spa Composizioni a base di ceppi batterici e estratti di bacche e loro uso come antinfiammatori
IT201900020422A1 (it) 2019-11-05 2021-05-05 Sofar Spa Composizioni comprendenti ceppi di batteri per uso per aumentare la biodisponibilità degli amminoacidi derivanti da proteine
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems

Also Published As

Publication number Publication date
CA2944118C (fr) 2020-06-30
US20230052820A1 (en) 2023-02-16
CA2944118A1 (fr) 2015-10-29
JP2017513906A (ja) 2017-06-01
US20170035816A1 (en) 2017-02-09
US11464814B2 (en) 2022-10-11
EP3134072A1 (fr) 2017-03-01
WO2015162570A1 (fr) 2015-10-29

Similar Documents

Publication Publication Date Title
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
IL256085B (en) A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment
TW201613901A (en) New compounds
IN2015DN01156A (fr)
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
PH12016501122A1 (en) Delayed release compositions of linaclotide
PH12016501702B1 (en) Pyrazole amide derivative
MX2015015518A (es) Metodos y composiciones para el tratamiento del cancer.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
IL251687A0 (en) Medicinal composition for use in treatment to prevent vitamin and mineral deficiencies in patients who have undergone gastric bypass surgery
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
MX2019000677A (es) Células miméticas de células b.
PH12017501694A1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
WO2016083315A8 (fr) Utilisation d'antagonistes d'ox1r pour le traitement de maladies intestinales inflammatoires
PH12015502305A1 (en) Use of pidotimod to treat inflammatory bowel disease
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.
IN2013MU03855A (fr)
UA93635U (uk) Фармацевтична композиція для лікування хронічних обструктивних захворювань легень
IN2014CH00035A (fr)